[go: up one dir, main page]

MX2023011686A - Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos. - Google Patents

Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.

Info

Publication number
MX2023011686A
MX2023011686A MX2023011686A MX2023011686A MX2023011686A MX 2023011686 A MX2023011686 A MX 2023011686A MX 2023011686 A MX2023011686 A MX 2023011686A MX 2023011686 A MX2023011686 A MX 2023011686A MX 2023011686 A MX2023011686 A MX 2023011686A
Authority
MX
Mexico
Prior art keywords
compounds
methods
same
tyrosine kinase
kinase inhibitor
Prior art date
Application number
MX2023011686A
Other languages
English (en)
Inventor
Kishor M Wasan
Chris Galliano
Supratik Mukhopadhyay
Adam Bess
Frej Knut Gosta Berglind
Stephania Cormier
Allan Ader
Nicholas Griggs
Janet Gould
Tiffany Cho
Julia Abramov
Peter Hnik
Michal Brylinski
Original Assignee
Skymount Medical Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skymount Medical Us Inc filed Critical Skymount Medical Us Inc
Publication of MX2023011686A publication Critical patent/MX2023011686A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un inhibidor de la tirosina quinasa para usar en el tratamiento de COVID-19 y/o sus síntomas asociados. También se describe un método para tratar a un individuo infectado con un coronavirus, en donde dicho método comprende los pasos de: proporcionar un inhibidor de tirosina quinasa; y administrar dicho inhibidor de tirosina quinasa a dicho individuo en una cantidad de dosificación suficiente para prevenir/estabilizar/reducir los riesgos y/o síntomas asociados con una infección por coronavirus.
MX2023011686A 2020-11-02 2023-05-02 Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos. MX2023011686A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA3097717A CA3097717A1 (en) 2020-11-02 2020-11-02 Tyrosine kinase in the treatment of coronavirus diseases
US202163165510P 2021-03-24 2021-03-24
US202163168766P 2021-03-31 2021-03-31

Publications (1)

Publication Number Publication Date
MX2023011686A true MX2023011686A (es) 2024-03-15

Family

ID=81381388

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023011283A MX2023011283A (es) 2020-11-02 2022-03-23 Uso de mebendazol para tratar infecciones virales.
MX2023011686A MX2023011686A (es) 2020-11-02 2023-05-02 Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2023011283A MX2023011283A (es) 2020-11-02 2022-03-23 Uso de mebendazol para tratar infecciones virales.

Country Status (5)

Country Link
US (1) US20230398114A1 (es)
JP (2) JP2023549180A (es)
CA (3) CA3097717A1 (es)
MX (2) MX2023011283A (es)
WO (2) WO2022094480A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036747A2 (en) * 2006-09-21 2008-03-27 Amarillo Biosciences, Inc. Composition and method for immunomodulation
CA3172586A1 (en) * 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
WO2015157223A1 (en) * 2014-04-07 2015-10-15 University Of Maryland, Baltimore Methods of treating coronavirus infection
US10610564B2 (en) * 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
WO2017141137A1 (en) * 2016-02-16 2017-08-24 Shoket Latief A composition and dosage form for reducing an hiv viral load
GB2559162A (en) * 2017-01-27 2018-08-01 Univ Bradford Compound for use in medicine
CN114191553B (zh) * 2020-05-27 2024-01-02 中国医学科学院病原生物学研究所 抗新型冠状病毒SARS-CoV-2的药物及其应用

Also Published As

Publication number Publication date
WO2022094480A1 (en) 2022-05-05
CA3213205A1 (en) 2022-09-29
CA3097717A1 (en) 2022-05-02
MX2023011283A (es) 2023-12-07
JP2024512051A (ja) 2024-03-18
US20230398114A1 (en) 2023-12-14
WO2022204318A2 (en) 2022-09-29
WO2022204318A3 (en) 2022-12-15
CA3197141A1 (en) 2022-05-05
JP2023549180A (ja) 2023-11-22

Similar Documents

Publication Publication Date Title
PH12022552486A1 (en) Inhibitors of norovirus and coronavirus replication
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2020009773A (es) Terapia de combinacion.
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
MX2020010322A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
AR045268A1 (es) Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
EA200600200A1 (ru) Способ лечения синдрома отвыкания от зависимости
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
PH12022551110A1 (en) Methods of treating depressive disorders
RU2011123367A (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2021001764A (es) Terapia de combinacion.
MX2023011686A (es) Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos.
AR125121A1 (es) Actividad antiviral de inhibidores de vps34
MX2023001570A (es) Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.